Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

• Type of Material: Article
• Authors: M S Topp, Universitätsklinikum Würzburg; M Stelljes, University of Münster; G Zugmaier, Amgen Research (Munich) GmbH; P Barnette, Primary Children's Hospital; L Thompson Heffner Jr., Emory University; T Trippett, Memorial Sloan-Kettering Cancer Center; J Duell, Universitätsklinikum Würzburg; R C Bargou, University Hospital; C Holland, Amgen Inc.; J E Benjamin, Amgen Inc.; M Klinger, Amgen Research (Munich) GmbH; M R Litzow, Mayo Clinic
• Language: English
• Date: 2018-02-01
• Publisher: Nature Publishing Group
• Publication Version: Final Published Version
• Copyright Statement: © 2018 The Author(s)
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1038/leu.2017.306
• Title of Journal or Parent Work: Leukemia
• ISSN: 0887-6924
• Volume: 32
• Issue: 2
• Start Page: 562
• End Page: 565
• Grant/Funding Information: This study was supported by research funding from Amgen Inc. Geoff Smith of Amgen Inc.
• Keywords: Oncology; CELLS; Hematology; Life Sciences & Biomedicine; Science & Technology
• Research Categories: Health Sciences, Oncology